GlassScriptPhysician profile
Michael A Childs
NPI 1568669448
$8,054.21
in general payments reported to CMS, 2019-2025
43 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $588 · 2021: $756 · 2022: $679 · 2023: $1,628 · 2024: $1,718 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Travel and Lodging: $495 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.33 |
| Travel and Lodging | $494.80 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,085.41 | 2019-2025 | Axonics, General - Erectile Dysfunction, Ams 700 |
| Teleflex LLC | $1,021.43 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $723.57 | 2019-2025 | Erleada, Akeega |
| Axonics, INC. | $654.12 | 2020-2024 | Axonics, Bulkamid |
| Dendreon Pharmaceuticals LLC | $648.65 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $466.86 | 2019-2024 | Xtandi |
| Procept Biorobotics Corporation | $424.33 | 2020-2025 | Aquabeam System, Aquabeam Robotic System |
| Coloplast Corp | $356.81 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $241.00 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $236.62 | 2020-2025 | |
| Pfizer INC. | $197.15 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $177.63 | 2020-2025 | Prolaris, Myrisk |
| Olympus America INC. | $143.50 | 2023-2025 | Itind System |
| Medtronic, INC. | $141.36 | 2023-2024 | Interstim |
| Accord Healthcare, INC. | $117.40 | 2023-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $107.76 | 2020-2023 | |
| Verity Pharmaceuticals INC. | $105.15 | 2024-2025 | Trelstar |
| Agiliti Health, INC. | $101.04 | 2024-2025 | Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Neotract INC. | $100.27 | 2019-2020 | |
| Tolmar, INC. | $90.65 | 2023-2025 | Jatenzo, Eligard |
| Abbvie INC. | $86.08 | 2022-2025 | |
| Allergan, INC. | $69.94 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $64.36 | 2021-2024 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $59.74 | 2020-2024 | Keytruda |
| 180 Medical, INC. | $49.01 | 2021-2024 | Gentlecath Glide |
| Ferring Pharmaceuticals INC. | $48.15 | 2019-2020 | |
| Myovant Sciences INC. | $47.97 | 2021-2022 | |
| Endo USA, INC. | $46.61 | 2024-2025 | Xiaflex |
| Rochester Medical Corporation | $44.78 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $43.45 | 2023 | Seglentis |
| Halozyme INC | $41.33 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $37.31 | 2022 | |
| Conmed Corporation | $37.01 | 2023-2024 | Airseal |
| Urogen Pharma, INC. | $33.94 | 2023-2025 | Jelmyto |
| Urovant Sciences INC | $32.00 | 2022 | |
| Antares Pharma, INC. | $29.70 | 2024-2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $26.69 | 2022 | |
| Medtronic USA, INC. | $26.09 | 2020 | |
| Acell, INC. | $24.00 | 2019 | |
| Laborie Medical Technologies Corp. | $17.34 | 2025 | |
| Cure Medical LLC | $16.68 | 2020 | |
| Amgen INC. | $15.78 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.54 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.